Parenteral and Inhaled Prostanoid Therapy in the Treatment of Pulmonary Arterial Hypertension
被引:35
|
作者:
McLaughlin, Vallerie V.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Michigan Hosp & Hlth Syst, Ctr Cardiovasc, Pulm Hypertens Program, Ann Arbor, MI 48109 USAUniv Michigan Hosp & Hlth Syst, Ctr Cardiovasc, Pulm Hypertens Program, Ann Arbor, MI 48109 USA
McLaughlin, Vallerie V.
[1
]
Palevsky, Harold I.
论文数: 0引用数: 0
h-index: 0
机构:
Penn Presbyterian Med Ctr, Pulm Vasc Dis Program, Philadelphia, PA 19104 USAUniv Michigan Hosp & Hlth Syst, Ctr Cardiovasc, Pulm Hypertens Program, Ann Arbor, MI 48109 USA
Palevsky, Harold I.
[2
]
机构:
[1] Univ Michigan Hosp & Hlth Syst, Ctr Cardiovasc, Pulm Hypertens Program, Ann Arbor, MI 48109 USA
[2] Penn Presbyterian Med Ctr, Pulm Vasc Dis Program, Philadelphia, PA 19104 USA
Since continuous IV epoprostenol was approved in the U.S., parenteral prostanoid therapy has remained the gold standard for the treatment of patients with advanced pulmonary arterial hypertension (PAH). Prostanoid agents can be administered as continuous intravenous infusions, as continuous subcutaneous infusions and by intermittent nebulization therapy. This article presents data from clinical trials of available prostanoid agents, and their varied routes of administration. The varied routes of administration allow for the incremental use of this class of agents in advanced PAH, and if PAH progresses. Prostanoids will remain a major component of PAH therapy for the foreseeable future.
机构:
Univ Chicago Med, Sect Pulm & Crit Care Med, 5841 S Maryland Ave, Chicago, IL 60637 USAUniv Chicago Med, Sect Pulm & Crit Care Med, 5841 S Maryland Ave, Chicago, IL 60637 USA
Kimmig, Lucas M.
Liao, Chuanhong
论文数: 0引用数: 0
h-index: 0
机构:
Univ Chicago, Dept Publ Hlth Sciences, 5841 S Maryland Ave, Chicago, IL 60637 USAUniv Chicago Med, Sect Pulm & Crit Care Med, 5841 S Maryland Ave, Chicago, IL 60637 USA